(Date:1/8/2009)...it lowered bad cholesterol more effectively than Z...s) -- After nearly a year of review, U.S. health o...tinued use of the controversial cholesterol-loweri...istration said there was no significant difference...ng Vytorin and patients taking the drug Zocor. ,...
(Date:1/8/2009)... of local dance students will dance to raise money...POLIS, Jan. 8 , , , WHO: ...ll show off their talent in the 3rd annual Dance,...y Dance Arts Centre. The, event w...or., Participants raise money th...
(Date:1/8/2009)...AGO, Jan. 8 Allscripts-M...pts Healthcare Solutions, Inc. (Allscripts or,the...or the three and six,months ended November 30, 20...n/prnh/20061005/ALLSCRIPTSLOGO-b ) , The Co... November 30, 2008,include results from legacy Al...
(Date:1/8/2009)...FRANCISCO, Jan. 8 Mediva... David Hung, M.D., president and chief,executive ...an Healthcare,Conference on Wednesday, January 14...ancis Hotel in San Francisco. , Dr. Hung wi...cal,development programs for Dimebon for Alzheime...
Breaking Medicine News(10 mins):Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Dance With Courage to Benefit Camp Courage 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2(Date:1/6/2009)...BRIDGE, Mass., Jan. 6 Cequent Phar... products to deliver RNAi-based treatments to prev...mpany has recently completed a successful toxicolo...stered tk RNAi therapeutic targeting the primary ...denomatous polyposis). FAP is an inherited gastroi...
(Date:1/5/2009)... SAN JOSE, Calif., Jan. 5 Women un...gesterone medication to help support early,pregna...ms of this medication,can be painful for patients...can be administered by subcutaneous injection or v... better patient tolerance. , With patient w...
(Date:12/27/2008)... SAN DIMAS, Calif., Dec. 27 Accord... are best advised to consume modest doses of,resv...typically provided in 3,to 5 glasses of aged, red...oto: http://www.newscom.com/cgi-bin/prnh/2008060...mega-dose resveratrol alone fails to prolong,the ...
(Date:12/17/2008)...TO, Calif., Dec. 17 PEAK Surgical,...d a new tissue dissection system based on a,propr...ood and Drug,Administration (FDA) has granted the...urgery System for cutting and coagulation of soft ...r, nose and throat), gynecologic,orthopedic, art...
Breaking Medicine Technology:Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 1EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 2EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 3Concentric Medical 28R 29 Announces Co Marketing Agreement With InTouch Health 28R 29 to Advance Acute Ischemic Stroke Care 7088 1Concentric Medical 28R 29 Announces Co Marketing Agreement With InTouch Health 28R 29 to Advance Acute Ischemic Stroke Care 7088 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan Kettering Institute for Cancer Research 2820 1MabVax Therapeutics Closes Two Licensing Agreements With Sloan Kettering Institute for Cancer Research 2820 2Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 1Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 2Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 3...)--Jun 4, 2007 - Introgen Therapeutics, Inc.,(NASD... today,reported updated Phase 2 data demonstrating...umor responses and increased,survival following AD...us cell carcinoma of the head and neck. The data (... meeting of the American,Society of Clinical Oncol...
...se 2 Clinical Data Published at the American,Socie...GO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmi...m its Phase II,multi-center clinical study of Amr...nthracycline currently in development,for the trea...dicate favorable interim results in terms of respo...
Other Medicine Technology:Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 4The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements.
Colour video monitors.
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty.
Camera and light source in one compact "Plug-and-Play" device.
Medicine Products: